BURLINGTON, Mass., Dec. 7, 2010 /PRNewswire/ — InfraReDx, Inc., a medical
device company developing intelligent cardiovascular diagnostic
imaging technologies, today announced the publication of a case
report in Circulation describing the association of stent
thrombosis with lipid core plaque as detected by its
LipiScan™ Coronary Imaging System. The LipiScan is the first
and only FDA-approved system to provide a Chemogram™ (map of
lipid core plaque) within the imaged vessel via near-infrared (NIR)
spectroscopy. The authors note that the case represents the first
demonstration of acute stent thrombosis associated with disrupted
lipid core plaque (LCP) as detected by NIR imaging with the
LipiScan system.
The paper titled “Residual Thrombogenic Substrate After Rupture
of a Lipid Rich Plaque – Possible Mechanism of Acute Stent
Thrombosis? A Near-Infrared Spectroscopy Study” was published in
Circulation (2010;122:2349-2350) under authors Sakhuja R.,
Suh W., Jaffer F. and Jang I.
“While stenting is an excellent means to treat flow restrictions
caused by coronary plaques, it is in some cases complicated by
thrombosis which may cause serious consequences,” said James E.
Muller, M.D., founder and chief executive officer of InfraReDx.
“This report by Sakhuja et al. describes the occurrence of
thrombosis in a stent that ends in a lipid core plaque, a structure
that contains substances known to be thrombogenic. This adds to the
accumulating evidence that many complications of stenting –
peri-stenting infarction, stent thrombosis and restenosis –
are due not to features of the stent or stenting technique, but to
the presence of a lipid core plaque at the stented site. We are
pleased to make available the LipiScan IVUS Coronary Imaging
System, which provides an easy and accurate method to detect lipid
core plaque and thereby adds important information to the
decision-makin
‘/>”/>
